Financial analysis of gsk

Learn More Brii Biosciences is committed to bringing innovative medicines to China as a way to improve public health. We bring together clinically differentiated assets to meet this challenge, supported by world-class leadership, advisors, partners, and funders. The pace of innovation has accelerated over the past decade, resulting in dramatically better treatments and cures for life-threatening diseases. Unfortunately, these innovations have not always reached China or the patients in China who need them.

Financial analysis of gsk

Learn More Brii Biosciences is committed to bringing innovative medicines to China as a way to improve public health. We bring together clinically differentiated assets to meet this challenge, supported by world-class leadership, advisors, partners, and funders. The pace of innovation has accelerated over the past decade, resulting in dramatically better treatments and cures for life-threatening diseases.

Unfortunately, these innovations have not always reached China or the patients in China who need them. Breakthroughs in science and technology, and advances in digital and data capabilities, are poised to disrupt the discovery, development and delivery of medicines. At the same time, the regulatory environment in China has improved significantly.

Leadership Team The Brii Bio leadership team includes industry-leading scientists with a strong track record of discovering and developing novel medicines.

Financial analysis of gsk

Prior to starting Brii Bio, Dr. GSK now has one of the most innovative pipelines against infectious diseases. Hong is a public health advocate who has helped establish multiple public-private partnerships with the U.

Hong started Ardea Biosciences later acquired by AstraZeneca. Hong has more than 25 years of experience in drug discovery and development and has brought more than 30 compounds into development, including many that have been approved and launched.

Growth, Profitability, and Financial Ratios for GlaxoSmithKline PLC ADR (GSK) from rutadeltambor.com

He is accountable for developing and driving execution of clinical development programs and registrations in China. Prior to joining the company, Dr. Yan was Vice President and Head Unit Physician of GSK Oncology, where he oversaw global development of oncology assets focusing on immunotherapy, cancer epigenetics, and cell therapy.

Prior to his tenure at GSK, he was Executive Director at Merck responsible for clinical development of oncology, respiratory and immunology, infectious diseases, and vaccines in emerging markets.

He has published over 80 manuscripts and book chapters.

Leadership Team

He is also an alumnus of the Harvard Business School enterprise executive program. Xu had an illustrious career at Gilead Sciences where she was a senior director, a co-inventor of several successful antiviral therapies, and led the discovery efforts in many therapeutic areas against HIV, HCV, HBV, and cancers resulting in numerous clinical candidates.

Prior to Gilead, Dr. Xu worked at Abbott Laboratories now AbbVie in the fields of anti-inflammatory and anti-cancer research. Xu holds a B. She has co-authored more than 30 peer-reviewed scientific publications and holds more than 30 issued patents and applications.

Girardet served as Vice President, Pharmaceutical and Translational Sciences at Ardea Biosciences, a member of the AstraZeneca Group, where he led the progression of Ardea's internal discovery programs from concept to clinical development, and eventually to approval.

Girardet assisted the business development group in the sale of Ardea Biosciences to AstraZeneca, and in the successful licensing of refametinib to Bayer Healthcare.

He supervised Ardea's GMP productions during clinical trials of refametinib, lesinurad, and verinurad. Girardet was Senior Director, Discovery Logistics, at Ardea Biosciences where he managed all of Ardea's drug substance GMP production and directed the intellectual property team to secure the company's assets.

Earlier in his career, Dr. He has co-authored more than 45 peer-reviewed publications and book chapters, and is an inventor on more than 30 U. Zhu spent 10 years at MedImmune in the United States, where she served as the Director of Infectious Diseases and Vaccines with a particular focus in the fields of antiviral biologics and novel biotherapeutics.

Earlier in her career, Dr.Nov 13,  · Updated key statistics for GlaxoSmithKline PLC ADR - including gsk margins, P/E ratio, valuation, profitability, company description, and other stock analysis data.

Brii Biosciences – Breakthrough innovation & insight

by SIX Financial. GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations.

The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and rutadeltambor.com: € The information contained on this Annual Report summary page of rutadeltambor.com is a summary of and contains extracts from the GSK Annual Report and Accounts The summary or extracts alone do not contain sufficient information to allow a full understanding of the results and state of affairs of GlaxoSmithKline PLC or the GSK .

Latest Breaking news and Headlines on NeuroMetrix, Inc. (NURO) stock from Seeking Alpha. Read the news as it happens! Brii Biosciences is committed to bringing innovative medicines to China as a way to improve public health. We bring together clinically differentiated assets to meet this challenge, supported by world-class leadership, advisors, partners, and funders.

Brii Biosciences is committed to bringing innovative medicines to China as a way to improve public health. We bring together clinically differentiated assets to meet this challenge, supported by world-class leadership, advisors, partners, and funders.

Growth, Profitability, and Financial Ratios for GlaxoSmithKline PLC ADR (GSK) from rutadeltambor.com